Immunomodulatory role of proteinase-activated receptor-2

Annals of the Rheumatic Diseases

Volumn 71, Issue 9, 2012, Pages 1559-1566

  Crilly, Anne ^a   Palmer, Helen ^a   Nickdel, Mohammad B ^a   Dunning, Lynette ^a   Lockhart, John C ^a   Plevin, Robin ^b   Mcinnes, Iain B ^c   Ferrell, William R ^c  

^a UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROTEINASE ACTIVATED RECEPTOR 2;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTHRITIS; ARTICLE; CELL INFILTRATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; IMMUNOGENETICS; IMMUNOHISTOLOGY; IMMUNOMODULATION; IMMUNOREGULATION; JOINT INJURY; LYMPH NODE CELL; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINASE ACTIVATED RECEPTOR 2 GENE; REGULATOR GENE; SPLEEN; WILD TYPE;

EID: 85027921338     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200869     Document Type: Article

References (32)

1. Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63. (Pubitemid 37553561)
2. Castro-Rueda H, Kavanaugh A. Biologic therapy for early rheumatoid arthritis: the latest evidence. Curr Opin Rheumatol 2008;20:314-9. (Pubitemid 351483322)
3. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
4. Williams RO. Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol Med 2004;98:207-16.
5. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42. (Pubitemid 46834849)
6. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19. (Pubitemid 351986171)
7. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-82. (Pubitemid 32476117)
8. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002;54:203-17. (Pubitemid 34575710)
9. Ferrell WR, Lockhart JC, Kelso EB, et al. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 2003;111:35-41. (Pubitemid 36134846)
10. Kelso EB, Lockhart JC, Hembrough T, et al. Therapeutic promise of proteinaseactivated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther 2006;316:1017-24. (Pubitemid 43345273)
11. Busso N, Frasnelli M, Feifel R, et al. Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum 2007;56:101-7. (Pubitemid 46106182)
12. Kelso EB, Ferrell WR, Lockhart JC, et al. Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum 2007;56:765-71. (Pubitemid 46399423)
13. Shpacovitch V, Feld M, Hollenberg MD, et al. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 2008;83:1309-22. (Pubitemid 351960309)
14. Fields RC, Schoenecker JG, Hart JP, et al. Protease-activated receptor-2 signaling triggers dendritic cell development. Am J Pathol 2003;162:1817-22. (Pubitemid 36613040)
15. Inglis JJ, Simelyte E, McCann FE, et al. Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc 2008;3:612-8. (Pubitemid 351516757)
16. Wei XQ, Leung BP, Arthur HM, et al. Reduced incidence and severity of collageninduced arthritis in mice lacking IL-18. J Immunol 2001;166:517-21. (Pubitemid 32038471)
17. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89. (Pubitemid 43214587)
18. Chung Y, Chang SH, Martinez GJ, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009;30:576-87.
19. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199-204. (Pubitemid 23097410)
20. Li T, He S. Induction of IL-6 release from human T cells by PAR-1 and PAR-2 agonists. Immunol Cell Biol 2006;84:461-6. (Pubitemid 44286040)
21. Shichijo M, Kondo S, Ishimori M, et al. PAR-2 deficient CD4+ T cells exhibit downregulation of IL-4 and upregulation of IFN-gamma after antigen challenge in mice. Allergol Int 2006;55:271-8. (Pubitemid 44433595)
22. Lewkowich IP, Day SB, Ledford JR, et al. Protease-activated receptor 2 activation of myeloid dendritic cells regulates allergic airway inflammation. Respir Res 2011;12:122.
23. Ramelli G, Fuertes S, Narayan S, et al. Protease-activated receptor 2 signalling promotes dendritic cell antigen transport and T-cell activation in vivo. Immunology 2010;129:20-7.
24. Kelso EB, Dunning L, Lockhart JC, et al. Strain dependence in murine models of monoarthritis. Inflamm Res 2007;56:511-4.
25. Ferrell W, Kelso E, Lockhart J, et al. Development of adjuvant monarthritis is critically dependent on the induction protocol: comment on the article by Busso et al. Arthritis Rheum 2007;56:3510. (Pubitemid 47585451)
26. Mohamadzadeh M, Mohamadzadeh H, Brammer M, et al. Identification of proteases employed by dendritic cells in the processing of protein purified derivative (PPD). J Immune Based Ther Vaccines 2004 2004;2:2-8.
27. Chen C, Darrow AL, Qi JS, et al. A novel serine protease predominately expressed in macrophages. Biochem J 2003;374:97-107. (Pubitemid 37046933)
28. Biro A, Sarmay G, Rozsnyay Z, et al. A trypsin-like serine protease activity on activated human B cells and various B cell lines. Eur J Immunol 1992;22:2547-53.
29. Tindell AG, Kelso EB, Ferrell WR, et al. Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis. Rheumatol Int 2011 doi:10.1007/s00296-011-2012-9.
30. Crilly A, Burns E, Nickdel MB, et al. PAR2 expression in peripheral blood monocytes of patients with rheumatoid arthritis. Ann Rheum Dis January 30 2012 doi:10.1136/annrheumdis-2011-200703.
31. Barry GD, Suen JY, Le GT, et al. Novel agonists and antagonists for human protease activated receptor 2. J Med Chem 2010;53:7428-40.
32. Suen JY, Barry GD, Lohman, et al. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol 2012;165:1413-23.